{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:00:52Z","timestamp":1784689252451,"version":"3.55.0"},"reference-count":24,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"abstract":"Abstract<\/jats:title>\n \n Background and Objectives<\/jats:title>\n This descriptive retrospective study evaluated the content, completeness and usability of information available in the Human Pluripotent Stem Cell Registry (hPSCreg\u00ae), including registered cell lines, research projects, clinical studies, donor characteristics and regulatory information.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n We analysed data registered in hPSCreg\u00ae from January 2008 to December 2021. We analysed the data regarding cell lines, research projects, clinical studies, diseases, countries and legal issues.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were 7538 total cell lines registered in the hPSCreg\u00ae. The most common derivation and generation countries were the United Kingdom, the United States, Germany and China. There were 3139 (46.5%) cell lines labelled as readily obtainable for a third party; few (7.2%) were labelled as available for commercial use. The most common diseases of the donor were Parkinson's disease, Alzheimer's disease and diabetes mellitus. Complete characterization data were available for the minority of the cell lines. The most common sponsor of research projects registered in the hPSCreg\u00ae was the European Union's Seventh Framework Programme (FP7). There were 97 registered clinical trials in the hPSCreg\u00ae. Challenges identified were incomplete user\u2010entered information, entry of non\u2010standardized information about diseases and continuing verification of the evolving legal status of embryonic stem cell (ESC) research per country.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The hPSCreg\u00ae represents an important international resource for stem cell research; however, this evaluation identified substantial variation in data completeness and standardization across registry fields. Future development should focus on improving the completeness of key metadata, standardization of terminology and systematic monitoring of registry data quality.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/vox.70332","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:01:28Z","timestamp":1784685688000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of data from the\n hPSCreg<\/scp>\n \u00ae, a global registry for human pluripotent stem cell lines (\n hPSC<\/scp>\n \u2010lines)"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-6061","authenticated-orcid":false,"given":"Livia","family":"Puljak","sequence":"first","affiliation":[{"name":"Faculty of Health Studies, School of Medicine, Center for Evidence\u2010Based Medicine Catholic University of Croatia Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kurtz","sequence":"additional","affiliation":[{"name":"BIH Center for Regenerative Therapies Berlin Institute of Health at Charite Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvonimir","family":"Koporc","sequence":"additional","affiliation":[{"name":"Faculty of Health Studies, School of Medicine, Center for Evidence\u2010Based Medicine Catholic University of Croatia Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2217\/17460751.3.6.945","article-title":"Development of a European human embryonic stem cell registry","volume":"3","author":"Borstlap J","year":"2008","journal-title":"Regen Med"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nbt0808-859","article-title":"First evaluation of the European hESCreg","volume":"26","author":"Borstlap J","year":"2008","journal-title":"Nat Biotechnol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101539","article-title":"A pathway for attesting ethical provenance of cell lines: lessons from the European human pluripotent stem cell registry (hPSC(reg))","volume":"40","author":"Isasi R","year":"2019","journal-title":"Stem Cell Res"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.101887","article-title":"Access to stem cell data and registration of pluripotent cell lines: The Human Pluripotent Stem Cell Registry (hPSCreg)","volume":"47","author":"Mah N","year":"2020","journal-title":"Stem Cell Res"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"D757","DOI":"10.1093\/nar\/gkv963","article-title":"hPSCreg\u2014the human pluripotent stem cell registry","volume":"44","author":"Seltmann S","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.stemcr.2018.06.012","article-title":"Recent trends in research with human pluripotent stem cells: impact of research and use of cell lines in experimental research and clinical trials","volume":"11","author":"Guhr A","year":"2018","journal-title":"Stem Cell Reports"},{"key":"e_1_2_9_8_1","unstructured":"hPSCreg\u00ae.How to register. Validation process. Available from:https:\/\/hpscreg.eu\/about\/registration. Last accessed 16 Jul 2026."},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12015-019-09935-x","article-title":"Advances in pluripotent stem cells: history, mechanisms, technologies, and applications","volume":"16","author":"Liu G","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.841107","article-title":"iPSC\u2010derived natural killer cell therapies\u2014expansion and targeting","volume":"13","author":"Goldenson BH","year":"2022","journal-title":"Front Immunol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.14348\/molcells.2021.0078","article-title":"iPSC\u2010derived natural killer cells for cancer immunotherapy","volume":"44","author":"Karagiannis P","year":"2021","journal-title":"Mol Cells"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.tins.2022.05.001","article-title":"Induced pluripotent stem cells: a tool for modeling Parkinson's disease","volume":"45","author":"Bose A","year":"2022","journal-title":"Trends Neurosci"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","article-title":"Pluripotent stem cell\u2010based cell therapy\u2014promise and challenges","volume":"27","author":"Yamanaka S","year":"2020","journal-title":"Cell Stem Cell"},{"key":"e_1_2_9_14_1","unstructured":"Human Pluripotent Stem Cell Registry (hPSCreg). Available from:http:\/\/hpscreg.eu. Last accessed 16 Jul 2026."},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13238","article-title":"Human pluripotent stem cell registry: operations, role and current directions","volume":"55","author":"Kurtz A","year":"2022","journal-title":"Cell Prolif"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042153","article-title":"Regenerative stem cell therapy for neurodegenerative diseases: an overview","volume":"22","author":"Sivandzade F","year":"2021","journal-title":"Int J Mol Sci"},{"key":"e_1_2_9_17_1","unstructured":"European Union.Statements on Regulation (EU) 2021\/695 of the European Parliament and of the Council of 28 April 2021 establishing Horizon Europe\u2014the Framework Programme for Research and Innovation laying down its rules for participation and dissemination and repealing Regulations (EU) No 1290\/2013 and (EU) No 1291\/2013. Available from:https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32021C0512(01). Last accessed 16 Jul 2026."},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcyt.2022.08.001","article-title":"A risk\u2010based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell\u2010derived allogeneic cell therapies","volume":"25","author":"Dashnau JL","year":"2023","journal-title":"Cytotherapy"},{"key":"e_1_2_9_19_1","unstructured":"International Society for Stem Cell Research.Guidelines for stem cell research and clinical translation. Available from:https:\/\/www.isscr.org\/guidelines. Last accessed 16 Jul 2026."},{"key":"e_1_2_9_20_1","unstructured":"International Stem Cell Banking Initiative. Publications. Available from:https:\/\/www.iscbi.org\/publications. Last accessed 16 Jul 2026."},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.stemcr.2021.05.012","article-title":"ISSCR guidelines for stem cell research and clinical translation: the 2021 update","volume":"16","author":"Lovell\u2010Badge R","year":"2021","journal-title":"Stem Cell Reports"},{"key":"e_1_2_9_22_1","unstructured":"EuroStemCell.Regulation of stem cell research in Europe. Available from:https:\/\/www.eurostemcell.org\/regulation-stem-cell-research-europe. Last accessed 16 Jul 2026."},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.stemcr.2023.03.005","article-title":"History and current status of clinical studies using human pluripotent stem cells","volume":"18","author":"Kobold S","year":"2023","journal-title":"Stem Cell Reports"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.stemcr.2020.06.014","article-title":"A manually curated database on clinical studies involving cell products derived from human pluripotent stem cells","volume":"15","author":"Kobold S","year":"2020","journal-title":"Stem Cell Reports"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41536-020-00100-4","article-title":"Global trends in clinical trials involving pluripotent stem cells: a systematic multi\u2010database analysis","volume":"5","author":"Deinsberger J","year":"2020","journal-title":"Npj Regener Med"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.70332","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:01:31Z","timestamp":1784685691000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":24,"alternative-id":["10.1111\/vox.70332"],"URL":"https:\/\/doi.org\/10.1111\/vox.70332","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"vox.70332"}}